As of 2026-11-12, the EV/EBITDA ratio of Fulgent Genetics Inc (FLGT) is -6.58. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FLGT's latest enterprise value is 619.80 mil USD. FLGT's TTM EBITDA according to its financial statements is -94.20 mil USD. Dividing these 2 quantities gives us the above FLGT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.3x - 14.5x | 12.9x |
| Forward P/E multiples | 10.6x - 13.1x | 12.0x |
| Fair Price | (41.79) - (48.58) | (45.96) |
| Upside | -262.6% - -289.0% | -278.8% |
| Date | EV/EBITDA |
| 2026-11-11 | -6.58 |
| 2026-11-10 | -6.60 |
| 2026-11-09 | -6.70 |
| 2026-11-06 | -6.06 |
| 2026-11-05 | -4.71 |
| 2026-11-04 | -4.98 |
| 2026-11-03 | -4.90 |
| 2026-11-02 | -4.88 |
| 2026-10-30 | -5.23 |
| 2026-10-29 | -5.51 |
| 2026-10-28 | -5.47 |
| 2026-10-27 | -5.25 |
| 2026-10-26 | -5.13 |
| 2026-10-23 | -5.09 |
| 2026-10-22 | -5.07 |
| 2026-10-21 | -5.10 |
| 2026-10-20 | -5.16 |
| 2026-10-19 | -5.09 |
| 2026-10-16 | -5.02 |
| 2026-10-15 | -5.42 |
| 2026-10-14 | -5.34 |
| 2026-10-13 | -5.35 |
| 2026-10-12 | -5.46 |
| 2026-10-09 | -5.53 |
| 2026-10-08 | -5.29 |
| 2026-10-07 | -5.22 |
| 2026-10-06 | -5.22 |
| 2026-10-05 | -5.72 |
| 2026-10-02 | -5.46 |
| 2026-10-01 | -5.41 |
| 2026-09-30 | -5.60 |
| 2026-09-29 | -5.62 |
| 2026-09-28 | -5.69 |
| 2026-09-25 | -5.65 |
| 2026-09-24 | -5.48 |
| 2026-09-23 | -5.40 |
| 2026-09-22 | -5.51 |
| 2026-09-21 | -5.48 |
| 2026-09-18 | -5.52 |
| 2026-09-17 | -5.56 |
| 2026-09-16 | -5.50 |
| 2026-09-15 | -5.41 |
| 2026-09-14 | -5.24 |
| 2026-09-11 | -5.19 |
| 2026-09-10 | -5.10 |
| 2026-09-09 | -5.03 |
| 2026-09-08 | -5.12 |
| 2026-09-04 | -5.00 |
| 2026-09-03 | -4.98 |
| 2026-09-02 | -5.08 |